X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Betibeglogene autotemcel
Therapeutic Area: Genetic Disease Product Name: LentiGlobin
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
LentiGlobin gene therapy for sickle cell disease (bb1111) is an investigational treatment being studied as a potential one-time therapy for SCD.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
